New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented...

TW's Take: data from this trial exceeds all expectations.  IRVINE, CA / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company...

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

TW's Take: this is a solid hire as his experience dovetails nicely into getting the VenoValve acquired by a larger device company post approval. Appointment...

enVVeno Announces VenoValve Top Line Results…

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial...

TW's Take: outstanding data makes reimbursement and approval highly likely with significant post-approval uptake. I believe this sets the stage for an acquisition within...

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

TW's Take: data next week is the missing ingredient to finally send NVNO to a decent valuation. Next gen product positions them for eventual...

Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at...

TW's Take: looking forward to, what I believe will be, outstanding data presented in just over 2 weeks. These results could be the catalyst...

enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the...

TW's Take: very positive results sets the stage for approval if the efficacy data comes through as expected. We'll see that data in the...

NVNO in the News Today…Premium Subscriber Update

enVVeno (NVNO) put out a hat trick of press releases today. The news ranged from getting $28 million in a private placement to fundamental...

enVVeno Medical Announces New Expedited Development Plan for the enVVe® Transcatheter Based Replacement Venous...

TW's Take: this product has multi-billion dollar potential and it's great to see the timeline moved up by 6 months. Non-surgical implantation is a...

enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

TW's Take: company is exceeding expectations on all fronts. Great news. – 18 VenoValve patients enrolled over the final two months of the study – Surge...

enVVeno Medical Announces Private Placement of $28 Million

TW's Take: very positive getting top-notch investors to pay above the market. Financing risk now completely eliminated and the company is exceeding timelines on...

enVVeno Medical to Host Virtual KOL Event on July 18, 2023

TW's Take: we continue to believe this device is going to succeed and be a big deal for NVNO. IRVINE, CA / July 14, 2023...

enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming...

TW's Take: trial progressing well, results will come early next year which is a modest delay from the original timeline but expected in any...

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer

TW's Take: our view on NVNO remains that the product will gain approval and substantial sales, but likely remains off investors' radar screens until...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.